This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aethlon Medical (AEMD) Note: Extracorporeal Methods To Reduce Inflammation In Sepsis

SAN DIEGO, Jan. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

Yesterday, our President Rod Kenley presented an informative review of extracorporeal medical device strategies to treat sepsis at the 15th International Conference on Dialysis. He also had the opportunity to discuss some of the advances we have made in the field.  If you are not familiar with sepsis, it is a life-threatening blood infection that can trigger multiple organ failure and is a leading cause of death in intensive care units (ICU).  18 million cases of sepsis are diagnosed around the globe each year and candidate drug therapies have yet to demonstrate an ability to significantly improve survival rates.

When we initiated our sepsis research, the prevailing viewpoint seemed to be that sepsis was triggered by a hyperactive response of the immune system in an attempt to respond to overwhelming infection. This response is often called a "cytokine storm."  As a result of this predominant viewpoint, many experimental therapies solely focused on modulating the early inflammatory response phase of sepsis and did so without much success.  As it turns out, sepsis is far more complex as the exuberant inflammatory immune response occurring at the outset of sepsis is soon followed by a period of significant immune suppression.  Thus, therapies solely focused on the knocking down the initial immune response may actually accelerate the development of immunosuppression, which is associated with a majority of deaths in sepsis.  In other words, while sepsis is triggered by a hyper activation of the immune response, most sepsis patients actually die from immune paralysis.

As Rod points out in his presentation, evidence suggests that a successful extracorporeal strategy will have the ability to selectively eliminate multiple sepsis promoting factors from circulation without disrupting the production of anti-inflammatory cytokines or other elements that might further exasperate immune suppression.  This is the focus of a strategy we are proudly advancing with industry colleagues under a contract with the Defense Advanced Research Projects Agency (DARPA).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs